Company Encyclopedia
View More
name
HWPC
688799.SH
Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products in China. It offers medicines in the areas of digestive, respiratory, anti-infection, diabetes, cardiovascular, cerebrovascular, and other fields. The company also provides APIs and Intermediates. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.
3.097 T
688799.SHMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking46/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.00%B
    • Profit Margin14.90%A
    • Gross Margin60.71%A
  • Growth ScoreC
    • Revenue YoY-1.17%D
    • Net Profit YoY0.75%C
    • Total Assets YoY16.84%A
    • Net Assets YoY4.43%C
  • Cash ScoreC
    • Cash Flow Margin671.01%C
    • OCF YoY-1.17%D
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreB
    • Gearing Ratio28.36%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    HWPC: The company’s benidipine hydrochloride tablets are expected to win the national centralized drug procurement bid

    HWPC announced that its Benidipine Hydrochloride Tablets are expected to win the bid for national centralized drug procurement, with a price of 7.19 yuan per box, and the procurement period lasting until December 31, 2028. The estimated sales revenue for 2024 is 166,300 yuan, and for the first half of 2025, it is 5.0976 million yuan. Winning the bid will help expand sales scale, enhance market share and brand influence, and have a positive impact on future operating performance

    Zhitong·
    SH
    688799
    +2.18%
    Zhitong·
    SH
    688799
    +2.18%

    HWPC: The subsidiary's raw materials drug has received the approval notice for the listing application

    HWPC announced that its wholly-owned subsidiary Hunan HWPC Chiral Pharmaceuticals Co., Ltd. has received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for Isoproterenol Hydrochloride and Levonorgestrel Tartrate. Isoproterenol Hydrochloride is used to treat cardiogenic or infectious shock, while Levonorgestrel Tartrate is used to control blood pressure in acute hypotensive states. This will enrich the company's product line and enhance its core competitiveness

    Zhitong·
    SH
    688799
    +2.18%
    Zhitong·
    SH
    688799
    +2.18%

    HWPC: Obtained the drug registration certificate for Sodium Potassium Polyethylene Glycol

    HWPC announced on October 13th that the company recently received the Drug Registration Certificate for polyethylene glycol sodium potassium powder issued by the National Medical Products Administration. This medication is suitable for the treatment of chronic constipation and fecal impaction

    Zhitong·
    SH
    688799
    +2.18%
    Zhitong·
    SH
    688799
    +2.18%

    HWPC withdraws the registration application for Arolol hydrochloride tablets

    According to the Zhitong Finance APP, HWPC announced that the company recently received the "Notice of Termination of Drug Registration Application" approved and issued by the National Medical Products Administration, agreeing to the company's withdrawal of the registration application for Arolol Hydrochloride Tablets. Arolol Hydrochloride Tablets are mainly used for the treatment of primary hypertension (mild to moderate), angina pectoris, tachyarrhythmia, and essential tremor

    Zhitong·
    SH
    688799
    +2.18%
    Zhitong·
    SH
    688799
    +2.18%

    HWPC: Xu Xiaoqiang reduced his holdings by 0.9870% in September

    HWPC announced that from September 1, 2025, to September 12, 2025, shareholder Xu Xiaoqiang cumulatively reduced his holdings by 1.2961 million shares through centralized bidding, accounting for 0.9870% of the company's total share capital, with a reduction price range of 51.75 to 65.54 yuan/share, totaling 75.8397 million yuan; this reduction plan has been completed, and Xu Xiaoqiang currently holds 674,800 shares, accounting for 0.5139%, while Xu Yan's 18.48 million shares have not been reduced

    Zhitong·
    SH
    688799
    +2.18%
    Zhitong·
    SH
    688799
    +2.18%
    © 2025 Longbridge｜Disclaimer